Paul Alexander responde a los que demandan pruebas de que la preocupación por las vacunas COVID-19 está justificada [ENG]

10 visitas

votos: 2 · 3

karma: 52

Cuando todo esto termine entonces tendremos que rendir cuentas porque esto va más allá de simples errores. Hay algo de malversación, sí, la codicia que envuelve cualquier asunto, pero hay malversación real. Cualquiera que haya hecho algo malo (bajo Trump o Biden), cualquiera que se haya beneficiado, que haya abusado de su posición o que con sus acciones haya costado vidas, debe pasar un tiempo entre rejas. Esto es parte de la curación. ¡Queremos cárcel! Lista de enlaces a artículos médicos en el 1^er comentario.

paul alexander, covid-19, seguridad, efecto secundario, vacuna, riesgo

comentarios (16)

#1 function
*

Where is the evidence?

Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/

Fatal cerebral hemorrhage after COVID-19 vaccine:

pubmed.ncbi.nlm.nih.gov/33928772/

Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: www.sciencedirect.com/science/article/pii/S2666602221000409

Three cases of acute venous thromboembolism in women after vaccination against COVID-19: www.sciencedirect.com/science/article/pii/S2213333X21003929

Acute thrombosis of the coronary tree after vaccination against COVID-19: www.sciencedirect.com/science/article/abs/pii/S1936879821003988

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: pubmed.ncbi.nlm.nih.gov/33929487/

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/

Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): pubmed.ncbi.nlm.nih.gov/33871350/

Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: www.sciencedirect.com/science/article/pii/S0022510X21003014

Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: www.sciencedirect.com/science/article/abs/pii/S0735675721004381

Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: www.sciencedirect.com/science/article/abs/pii/S0033062021000505

Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: www.sciencedirect.com/science/article/abs/pii/S0953620521001904

COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: www.sciencedirect.com/science/article/pii/S1665268121000557

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): www.sciencedirect.com/science/article/pii/S1050173821000967

Roots of autoimmunity of…

1 k 40
#2 function
*

#1 Exacerbation of immune thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34075578/

First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34105244/

PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: www.nejm.org/doi/full/10.1056/NEJMc2106383

Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: www.nature.com/articles/s41586-021-03744-4

Myocarditis with COVID-19 mRNA vaccines: www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135

Myocarditis and pericarditis after COVID-19 vaccination: jamanetwork.com/journals/jama/fullarticle/2782900

Myocarditis temporally associated with COVID-19 vaccination: www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891.

COVID-19 Vaccination Associated with Myocarditis in Adolescents: pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/ped

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: pubmed.ncbi.nlm.nih.gov/33994339/

Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: www.sciencedirect.com/science/article/pii/S1553838921005789

COVID-19 vaccine-induced myocarditis: a case report with review of the literature: www.sciencedirect.com/science/article/pii/S1871402121002253

Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: www.sciencedirect.com/science/article/pii/S1936878X2100485X

Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: www.sciencedirect.com/science/article/pii/S002234762100617X

Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: www.sciencedirect.com/science/article/pii/S0167527321012286.

Acute myocarditis after administration of BNT162b2 vaccine: www.sciencedirect.com/science/article/pii/S2214250921001530

Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: www.sciencedirect.com/science/article/pii/S2352906721001573

Myocarditis following vaccination with BNT162b2 in a healthy male: www.sciencedirect.com/science/article/pii/S0735675721005362

Acute…

1 k 40
#3 function
*

#2 Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: pubmed.ncbi.nlm.nih.gov/34236331/

Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34435250/

COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: pubmed.ncbi.nlm.nih.gov/34186348/.

GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: www.sciencedirect.com/science/article/pii/S2666354621000065

Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: www.sciencedirect.com/science/article/pii/S0303846721004169

Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: www.sciencedirect.com/science/article/pii/S0165572821002186

Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: www.sciencedirect.com/science/article/pii/S2214250921000998.

Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: www.sciencedirect.com/science/article/pii/S0736467921006442

Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: www.sciencedirect.com/science/article/pii/S0035378721005853.

SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: www.sciencedirect.com/science/article/pii/S2049080121005343

Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: www.sciencedirect.com/science/article/pii/S2049080121007536

Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: www.sciencedirect.com/science/article/pii/S1201971221007049

Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: www.sciencedirect.com/science/article/pii/S0899707121003557.

New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: www.sciencedirect.com/science/article/pii/S0165572821001569

Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: www.sciencedirect.com/science/article/pii/S0165572821002137

Bell’s palsy and SARS-CoV-2 vaccines: an…

1 k 40
#4 function
*

#3 Allergic reactions after COVID-19 vaccination: putting the risk in perspective: pubmed.ncbi.nlm.nih.gov/34463751/

Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: pubmed.ncbi.nlm.nih.gov/33846043/ 188.

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: pubmed.ncbi.nlm.nih.gov/33752263/

COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/

Fatal brain hemorrhage after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33928772/

A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: pubmed.ncbi.nlm.nih.gov/34423106/

Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: pubmed.ncbi.nlm.nih.gov/33838206/

Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: pubmed.ncbi.nlm.nih.gov/34517079/

Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: pubmed.ncbi.nlm.nih.gov/34254291/

Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: pubmed.ncbi.nlm.nih.gov/34487581/

Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: pubmed.ncbi.nlm.nih.gov/33987882/

Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34138513/

Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: pubmed.ncbi.nlm.nih.gov/34446426/

Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: pubmed.ncbi.nlm.nih.gov/34365148/.

Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of…

0 k 20
#5 function
*

#4 Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/

celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: pubmed.ncbi.nlm.nih.gov/34261633/.

Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34256983/

Thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34332437/.

Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33845870/.

Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: pubmed.ncbi.nlm.nih.gov/34236343/

Acute myocardial infarction within 24 hours after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34364657/.

Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34287612/

central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/

Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: pubmed.ncbi.nlm.nih.gov/34402235/

Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/

Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34101024/

A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34137813/

Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34191218/

Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/

New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine:…

0 k 20
#6 function
*

#5 Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34462647/

Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34325334/

Tolosa-Hunt syndrome occurring after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34513398/

Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/

Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): pubmed.ncbi.nlm.nih.gov/34469919/.

Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: pubmed.ncbi.nlm.nih.gov/34516272/.

Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: pubmed.ncbi.nlm.nih.gov/34512961/

Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34077949/

Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34171435/

Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34447349/

Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34514078/

Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34406660/.

IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34509658/

A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34196469/.

Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: pubmed.ncbi.nlm.nih.gov/34350668/

Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34436620/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/.

COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: pubmed.ncbi.nlm.nih.gov/34509271/.

Report of the International…

0 k 20
#7 function
*

#6 U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: pubmed.ncbi.nlm.nih.gov/33929487/.

Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/

Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/

Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/.

Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/

Autoimmunity roots of thrombotic events after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34508917/

Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/

Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34373991/

Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34490632/

An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33909350/

Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: pubmed.ncbi.nlm.nih.gov/33981305/.

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. pubmed.ncbi.nlm.nih.gov/34272622/

Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. pubmed.ncbi.nlm.nih.gov/33877737/

Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34254476/

First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic,…

0 k 17
#8 function
*

#7 Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34620638/

Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: pubmed.ncbi.nlm.nih.gov/34650896/

Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34625447/

Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: pubmed.ncbi.nlm.nih.gov/34696248/

Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34548920/

Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): pubmed.ncbi.nlm.nih.gov/34672380/.

Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: pubmed.ncbi.nlm.nih.gov/34556531/.

Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: pubmed.ncbi.nlm.nih.gov/34535076/.

Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: pubmed.ncbi.nlm.nih.gov/34379914/.

Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: pubmed.ncbi.nlm.nih.gov/34545400/

Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34035134/

In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34688190/

Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: pubmed.ncbi.nlm.nih.gov/34782400/

Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34710832/

Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: pubmed.ncbi.nlm.nih.gov/34695859/

Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases:…

0 k 17
#9 function
*

#8 Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34546343/

Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34849183/

Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34853744/.

A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): pubmed.ncbi.nlm.nih.gov/34751429/.

Ocular adverse events following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34559576/

Depression after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34608345/.

Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34384129/.

Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/

Major artery thrombosis and vaccination against ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34839830/

Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/

Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.

Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781027/

Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/

Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/

Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138

Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34753210/.

Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34653943/.

Relapse of immune…

0 k 17
#10 function
*

#9 Hypersensitivity Myocarditis and COVID-19 Vaccines: pubmed.ncbi.nlm.nih.gov/34856634/.

Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7.

Acute myocardial infarction and myocarditis after COVID-19 vaccination: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/

Myocarditis after Covid-19 vaccination in a large healthcare organization: www.nejm.org/doi/10.1056/NEJMoa2110737

Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: jamanetwork.com/journals/jamacardiology/fullarticle/2783052

Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=

STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. pubmed.ncbi.nlm.nih.gov/34756746/

Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/

Myocarditis after COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34546329/.

Patients with acute myocarditis after COVID-19 mRNA vaccination:. jamanetwork.com/journals/jamacardiology/fullarticle/2781602.

Myocarditis after COVID-19 vaccination: a case series: www.sciencedirect.com/science/article/pii/S0264410X21011725?via=ihub.

Myocarditis associated with COVID-19 vaccination in adolescents: publications.aap.org/pediatrics/article/148/5/e2021053427/181357

Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. pubmed.ncbi.nlm.nih.gov/34704459/

Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230.

Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/

Myocarditis after COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S2352906721001603

Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy:…

0 k 17
#11 function
*

#10 Perimyocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34866957/

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: pubmed.ncbi.nlm.nih.gov/34849657/.

Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: pubmed.ncbi.nlm.nih.gov/34664804/

Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: pubmed.ncbi.nlm.nih.gov/34605853/

Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: pubmed.ncbi.nlm.nih.gov/34166671/

Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34744118/

Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: pubmed.ncbi.nlm.nih.gov/34334935/.

Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34746968/

Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: pubmed.ncbi.nlm.nih.gov/34333695/.

Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/

Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: pubmed.ncbi.nlm.nih.gov/34185045/

Myocarditis after BNT162b2 vaccination in a healthy male: pubmed.ncbi.nlm.nih.gov/34229940/

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: pubmed.ncbi.nlm.nih.gov/34133825/

Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34308326/.

Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: pubmed.ncbi.nlm.nih.gov/34866106/

Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/

Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with…

0 k 17
#15 function
*

#14 Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. www.ncbi.nlm.nih.gov/pubmed/34617315

Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. www.ncbi.nlm.nih.gov/pubmed/34333695

Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. www.ncbi.nlm.nih.gov/pubmed/34833382

Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. www.ncbi.nlm.nih.gov/pubmed/34704459

Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. www.ncbi.nlm.nih.gov/pubmed/34664804

Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. www.ncbi.nlm.nih.gov/pubmed/34860360

Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. www.ncbi.nlm.nih.gov/pubmed/34849657

Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. www.ncbi.nlm.nih.gov/pubmed/34933012

Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . .…

0 k 16
#16 function
*

#15 Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. www.ncbi.nlm.nih.gov/pubmed/34348657

Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. www.ncbi.nlm.nih.gov/pubmed/34351881

Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. www.ncbi.nlm.nih.gov/pubmed/33854395

Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. www.ncbi.nlm.nih.gov/pubmed/34446426

Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. www.ncbi.nlm.nih.gov/pubmed/34808708

Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. www.ncbi.nlm.nih.gov/pubmed/34347278

In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubme

Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. www.ncbi.nlm.nih.gov/pubmed/34463755

Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute…

0 k 16
#12 function
*

#11 A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): pubmed.ncbi.nlm.nih.gov/34871447/

Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/

A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: pubmed.ncbi.nlm.nih.gov/34370408/.

A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34703690/.

Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/

Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: onlinelibrary.wiley.com/doi/10.1002/ana.26218.

Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34482455/.

Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34114269/.

Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/

Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/

SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/

Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/

Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/ful.

Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: pubmed.ncbi.nlm.nih.gov/34522557/

Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34763263/.

Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/

Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2…

0 k 15
#13 function
*

#12 Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: pubmed.ncbi.nlm.nih.gov/34807248/

Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34148772/

Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: pubmed.ncbi.nlm.nih.gov/34702550/

Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty ): pubmed.ncbi.nlm.nih.gov/33895650/

Deaths associated with recently launched SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34425384/

A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: pubmed.ncbi.nlm.nih.gov/34703815/

COVID-19 vaccine-induced urticarial vasculitis: pubmed.ncbi.nlm.nih.gov/34369046/.

ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34280507/.

New-onset leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34241833/

Cutaneous small vessel vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34529877/.

Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33928638/

Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34836739/

Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; pubmed.ncbi.nlm.nih.gov/34495381/.

Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34327795

Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34660867/.

Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34659268/

Reactivation of IgA vasculitis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34848431/

Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34310759/.

Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: pubmed.ncbi.nlm.nih.gov/34720009/

A rare case of Henoch-Schönlein…

0 k 15
#14 function
*

#13 COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/

Adenopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625299/.

Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34292295/.

COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.

Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/

Lymphadenopathy associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33786231/

Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625301/.

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34332438/.

New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: pubmed.ncbi.nlm.nih.gov/34342187/.

Massive cervical lymphadenopathy following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34601889/

ANCA glomerulonephritis following Modern COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34081948/

Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34507942/.

Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/

Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/

Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: pubmed.ncbi.nlm.nih.gov/34825530/.

Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34000278/

COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: pubmed.ncbi.nlm.nih.gov/34655312/.

Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34187985/.

Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination…

0 k 15